Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 3;54(11):924–932. doi: 10.1038/sc.2016.58

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 International Spinal Cord Society

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

PMC Copyright notice

Effects of Etamsylate on GFAP and Iba-1expression at 10 days after SCC. (a, b) GFAP and Iba-1 immunoreactivity in glucose control (a) and Etamsylate-treated group (b). (c, d) Quantification of the immunofluorescence intensity (IFI)/area of GFAP and Iba-1. Scale bars=100 μm; n=6/group. *P<0.05. (e, g) Western blots were probed for GFAP and Iba-1, and β-actin was used as a loading control. (f, h) Quantification of the expression of GFAP and Iba-1; n=3/group. *P<0.05. (i, j) Quantification of mRNA levels of GFAP and Iba-1; n=3/group. *P<0.05.